The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?

doi:10.1136/esmoopen-2020-001042

Comment

. 2020 Sep;5(5):e001042.

doi: 10.1136/esmoopen-2020-001042.

The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?

Angela Dalia Ricci¹, Alessandro Rizzo², Giovanni Brandi²

Affiliations

¹ Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy. Electronic address: dalia.ricci@gmail.com.
² Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

PMID: 32994319
PMCID: PMC7526276
DOI: 10.1136/esmoopen-2020-001042

Comment

The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?

Angela Dalia Ricci et al. ESMO Open. 2020 Sep.

. 2020 Sep;5(5):e001042.

doi: 10.1136/esmoopen-2020-001042.

Authors

Angela Dalia Ricci¹, Alessandro Rizzo², Giovanni Brandi²

Affiliations

¹ Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy. Electronic address: dalia.ricci@gmail.com.
² Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

PMID: 32994319
PMCID: PMC7526276
DOI: 10.1136/esmoopen-2020-001042

No abstract available

Keywords: correspondence.

PubMed Disclaimer

Comment on

Molecular profile of BRCA-mutated biliary tract cancers.
Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushman M, Salem ME, Battaglin F, Baca Y, El-Deiry WS, Philip PA, Nassem M, Hall M, Marshall JL, Kocher F, Amann A, Wolf D, Korn WM, Lenz HJ, Seeber A. Spizzo G, et al. ESMO Open. 2020 Jun;5(3):e000682. doi: 10.1136/esmoopen-2020-000682. ESMO Open. 2020. PMID: 32576609 Free PMC article.

Cited by

Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application.
Ren X, Huang M, Weng W, Xie Y, Wu Y, Zhu S, Zhang Y, Li D, Lai J, Shen S, Lin J, Kuang M, Li X, Yu J, Xu L. Ren X, et al. Cell Rep Med. 2023 Nov 21;4(11):101277. doi: 10.1016/j.xcrm.2023.101277. Epub 2023 Nov 8. Cell Rep Med. 2023. PMID: 37944531 Free PMC article.
Laparoscopic vs open radical resection in management of gallbladder carcinoma: A systematic review and meta-analysis.
He S, Yu TN, Cao JS, Zhou XY, Chen ZH, Jiang WB, Cai LX, Liang X. He S, et al. World J Clin Cases. 2023 Sep 26;11(27):6455-6475. doi: 10.12998/wjcc.v11.i27.6455. World J Clin Cases. 2023. PMID: 37900219 Free PMC article.
HSDL2 knockdown promotes the progression of cholangiocarcinoma by inhibiting ferroptosis through the P53/SLC7A11 axis.
Ma S, Ma Y, Qi F, Lei J, Chen F, Sun W, Wang D, Zhou S, Liu Z, Lu Z, Zhang D. Ma S, et al. World J Surg Oncol. 2023 Sep 18;21(1):293. doi: 10.1186/s12957-023-03176-6. World J Surg Oncol. 2023. PMID: 37718459 Free PMC article.
Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review.
Zhang Z, Wang X, Li H, Sun H, Chen J, Lin H. Zhang Z, et al. Front Immunol. 2023 Aug 21;14:1230261. doi: 10.3389/fimmu.2023.1230261. eCollection 2023. Front Immunol. 2023. PMID: 37671157 Free PMC article. Review.
Review and Application of Integrin Alpha v Beta 6 in the Diagnosis and Treatment of Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma.
Lian Y, Zeng S, Wen S, Zhao X, Fang C, Zeng N. Lian Y, et al. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231189399. doi: 10.1177/15330338231189399. Technol Cancer Res Treat. 2023. PMID: 37525872 Free PMC article. Review.

See all "Cited by" articles

References

1. Spizzo G, Puccini A, Xiu J, et al. . Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open 2020;5:e000682. 10.1136/esmoopen-2020-000682 - DOI - PMC - PubMed
1. Heeke AL, Pishvaian MJ, Lynce F, et al. . Prevalence of homologous Recombination–Related gene mutations across multiple cancer types. JCO Precis Oncol 2018;2018:1–13. - PMC - PubMed
1. Park W, Chen J, Chou JF, et al. . Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res 2020;26:3239–47. 10.1158/1078-0432.CCR-20-0418 - DOI - PMC - PubMed
1. Kim RD, Chung V, Alese OB, et al. . A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol 2020;6:1–8. 10.1001/jamaoncol.2020.0930 - DOI - PMC - PubMed
1. Shim JH, Kim HS, Cha H, et al. . HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Ann Oncol 2020;31:902–11. 10.1016/j.annonc.2020.04.004 - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- Genetic Alliance

[1] Spizzo G, Puccini A, Xiu J, et al. . Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open 2020;5:e000682. 10.1136/esmoopen-2020-000682 - DOI - PMC - PubMed

[2] Spizzo G, Puccini A, Xiu J, et al. . Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open 2020;5:e000682. 10.1136/esmoopen-2020-000682 - DOI - PMC - PubMed

[3] Heeke AL, Pishvaian MJ, Lynce F, et al. . Prevalence of homologous Recombination–Related gene mutations across multiple cancer types. JCO Precis Oncol 2018;2018:1–13. - PMC - PubMed

[4] Heeke AL, Pishvaian MJ, Lynce F, et al. . Prevalence of homologous Recombination–Related gene mutations across multiple cancer types. JCO Precis Oncol 2018;2018:1–13. - PMC - PubMed

[5] Park W, Chen J, Chou JF, et al. . Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res 2020;26:3239–47. 10.1158/1078-0432.CCR-20-0418 - DOI - PMC - PubMed

[6] Park W, Chen J, Chou JF, et al. . Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res 2020;26:3239–47. 10.1158/1078-0432.CCR-20-0418 - DOI - PMC - PubMed

[7] Kim RD, Chung V, Alese OB, et al. . A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol 2020;6:1–8. 10.1001/jamaoncol.2020.0930 - DOI - PMC - PubMed

[8] Kim RD, Chung V, Alese OB, et al. . A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol 2020;6:1–8. 10.1001/jamaoncol.2020.0930 - DOI - PMC - PubMed

[9] Shim JH, Kim HS, Cha H, et al. . HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Ann Oncol 2020;31:902–11. 10.1016/j.annonc.2020.04.004 - DOI - PubMed

[10] Shim JH, Kim HS, Cha H, et al. . HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Ann Oncol 2020;31:902–11. 10.1016/j.annonc.2020.04.004 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?

Affiliations

The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical